# EDGAR Filing Document

**Accession Number:** 0001828185
**File Stem:** 0001104659-25-075707
**Filing Date:** 2025-8
**Character Count:** 24495
**Document Hash:** 9066f4febe0729ed25f2d1fddc6746ed
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-075707.hdr.sgml**: 20250808

**ACCESSION NUMBER**: 0001104659-25-075707

**CONFORMED SUBMISSION TYPE**: 8-K/A

**PUBLIC DOCUMENT COUNT**: 15

**CONFORMED PERIOD OF REPORT**: 20250807

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250808

**DATE AS OF CHANGE**: 20250808

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Barinthus Biotherapeutics plc.
- **CENTRAL INDEX KEY:** 0001828185
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** X0
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40367
- **FILM NUMBER:** 251198720

**BUSINESS ADDRESS:**
- **STREET 1:** 20400 CENTURY BLVD
- **STREET 2:** SUITE 210
- **CITY:** GERMANTOWN
- **STATE:** MD
- **ZIP:** 20874
- **BUSINESS PHONE:** 44 (0) 1865 818808

**MAIL ADDRESS:**
- **STREET 1:** 20400 CENTURY BLVD
- **STREET 2:** SUITE 210
- **CITY:** GERMANTOWN
- **STATE:** MD
- **ZIP:** 20874

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Vaccitech plc
- **DATE OF NAME CHANGE:** 20210407

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Vaccitech Ltd
- **DATE OF NAME CHANGE:** 20201014

?xml version='1.0' encoding='ASCII'?

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549** 

**FORM 8-K/A**

**(Amendment No. 1)** 

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** **August 7, 2025** 

**BARINTHUS BIOTHERAPEUTICS PLC**

**(Exact name of registrant as specified in its charter)** 

---

| | | |
|:---|:---|:---|
| **England and Wales** | **001-40367** | **Not Applicable** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |

---

**Barinthus Biotherapeutics plc**

**20400 Century Blvd, Suite 210**

**Germantown** **, MD 20874**

**(Address of principal executive offices, including zip code)**

**(443) 917-0966**

**(Registrant's telephone number, including area code)** 

**Not Applicable**

**(Former name or former address, if changed since last report)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trade Symbol(s) | Name of each exchange on which <br> registered |
| American Depositary Shares | BRNS | The Nasdaq Global Market |
| Ordinary shares, nominal value £0.000025 per share\* |  |  |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ⌧

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

\*American Depositary Shares may be evidenced by American Depositary Receipts. Each American Depositary Share represents one (1) ordinary share. Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8.

**EXPLANATORY NOTE**

Barinthus Biotherapeutics plc (the "Company") is filing this Amendment No. 1 on Form 8-K/A (this "Amendment") to amend its Current Report on Form 8-K furnished by the Company to the Securities and Exchange Commission (the "SEC") on August 7, 2025 (the "Original Report"). The Exhibit 99.1 to the Original Report inadvertently included an inaccurate statement in a sub-bullet describing the trial result of the Company's Phase 1 trial of VTP-850 in patients with prostate cancer. The sole purpose of this Amendment No is to correct the information in this sub-bullet in the Exhibit 99.1. No other changes have been made to the Original Report.

**Item 2.02. Results of Operations and Financial Condition.**

On August 7, 2025, Barinthus Biotherapeutics plc (the "Company") provided an overview of the Company's progress and announced its financial results for the quarter ended June 30, 2025. The full text of the press release issued in connection with the update is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01. Financial Statements and Exhibits.**

(d) Exhibits

[99.1](tm2523009d1_ex99-1.htm) [Press Release dated August 7, 2025.](tm2523009d1_ex99-1.htm) <br>104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | Barinthus Biotherapeutics plc | Barinthus Biotherapeutics plc |
| Date: August 8, 2025 | By: | /s/ William Enright |
|  |  | William Enright |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](tm2523009d1_ex99-img001.jpg)

**Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments**

&nbsp;&nbsp;&nbsp;&nbsp;· *The final cohort of the* *single ascending dose (SAD) part of the Phase 1 A VALON trial initiated, with the SAD data readout expected early in the fourth quarter of 2025;* 

&nbsp;&nbsp;&nbsp;&nbsp;· *The multiple ascending dose (MAD) part of the AVALON trial initiated;* 

· *Available resources and cash runway guidance into 2027 remains unchanged.* 

GERMANTOWN, Maryland, August 7, 2025 (GLOBE NEWSWIRE) – Barinthus Biotherapeutics plc (NASDAQ: BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation ("I&I") company focused on developing therapies that promote immune tolerance with curative potential, today announced its financial results for the quarter ended June 30, 2025, and provided an overview of the Company's corporate developments.

"In the second quarter, we remained laser-focused on advancing VTP-1000, our highly differentiated immunotherapy designed to prevent or reduce symptoms following gluten exposure in patients with celiac disease," said Bill Enright, Chief Executive Officer of Barinthus Bio. "We are currently screening patients for the last cohort of the SAD portion of the Phase 1 AVALON trial, and as planned, we initiated the MAD portion of the trial, which includes a gluten challenge, enabling us to assess the potential efficacy of VTP-1000 at this early stage. We look forward to reporting topline data from the SAD portion of the trial early in the fourth quarter of 2025."

**Recent Corporate Developments** 

*Clinical Developments and Upcoming Milestones* 

 

&nbsp;&nbsp;&nbsp;&nbsp;· Phase 1 AVALON trial of VTP-1000 in patients with celiac disease

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Part A: SAD:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· The first two cohorts have been dosed with no treatment related serious adverse events ("SAEs") reported.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· The third and final cohort in the SAD part of the trial is ongoing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· SAD data is expected early in the fourth quarter of 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Part B: MAD:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· MAD portion of the trial was initiated in July 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· MAD data is expected in mid-2026.

&nbsp;&nbsp;&nbsp;&nbsp;· Phase 1 trial of VTP-850 in patients with prostate cancer

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· The trial is now complete; VTP-850 was well tolerated in this population of elderly prostate cancer patients.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;· Data shows encouraging signs of immunogenicity and will be used
to facilitate partnering discussions.

*Corporate Updates*

 

&nbsp;&nbsp;&nbsp;&nbsp;· Barinthus Bio continues
to actively seek partners to advance its VTP-300 program in chronic hepatitis B, its VTP-850 program in prostate cancer and other viral
vector-based assets.

**Second** **Quarter 2025 Financial Highlights**

&nbsp;&nbsp;&nbsp;&nbsp;· **Cash:** As of June 30, 2025, cash, cash equivalents and restricted cash was $87.8
million, compared to $100.6 million as of March 31, 2025. The $12.8 million decrease is a result of the net cash used in operating activities
of $18.1 million for the development of our pipeline and general corporate expenses, offset by a $5.3 million translational gain from
the conversion of balances in pound sterling denominated entities to the United States dollar reporting currency. Based on current research
and development plans, the Company expects its available resources to fund its operating expenses and capital expenditure requirements
into 2027.

&nbsp;&nbsp;&nbsp;&nbsp;· **Research and Development Expenses:** Research and development expenses were $8.0 million
in the second quarter of 2025 compared to $8.3 million for the first quarter of 2025, with the decrease attributable to a reduction in
preclinical activity and a reduction in workforce. The quarter-on-quarter research and development expenses per program are outlined in
the following table, with the expense primarily attributable to completion and presentation of preliminary results data from the two phase
2 clinical trials of VTP-300 that were presented at the European Association for the Study of the Liver ("EASL") Congress
2025 in May, and the continued progression of the phase 1 AVALON clinical trial of VTP-1000 in celiac disease. It is anticipated that
research and development expenses related to the legacy programs in infectious disease and oncology will reduce going forward as the ongoing
clinical trials complete, and that research and development expenses related to autoimmune programs will continue or increase, as the
clinical development continues.

---

| | | | |
|:---|:---|:---|:---|
|  | **Three months<br> ended June 30, 2025** | **Three months<br> ended March 31, 2025** | **Change** |
|  | **$000** | **$000** | **$000** |
| Direct research and development expenses by program: |  |  |  |
| &nbsp;&nbsp;&nbsp;VTP-1000 Celiac | $1782 | $982 | $800 |
| &nbsp;&nbsp;&nbsp;VTP-300 HBV | 1837 | 1350 | 487 |
| &nbsp;&nbsp;&nbsp;Other clinical programs<sup>1</sup> | 642 | 741 | (99) |
| &nbsp;&nbsp;&nbsp;Other pre-clinical programs | 449 | 419 | 30 |
| Total direct research and development expenses | 4710 | 3492 | 1218 |
| Indirect research and development expenses: |  |  |  |
| &nbsp;&nbsp;&nbsp;Personnel-related (including share-based compensation)2 | 2450 | 3944 | (1494) |
| &nbsp;&nbsp;&nbsp;Facility related | 350 | 335 | 15 |
| &nbsp;&nbsp;&nbsp;Other indirect costs | 443 | 519 | (76) |
| Total indirect research and development expenses | 3243 | 4798 | (1555) |
| Total research and development expense | $7953 | $8290 | $(337) |

---

*<sup>1</sup> This includes expenses relating to the infectious disease and oncology programs; VTP-850 Prostate cancer, VTP-200 HPV, VTP-600 NSCLC (the Phase 1/2a trial is sponsored by Cancer Research UK) and VTP-500 MERS (funded pursuant to an agreement with the Coalition for Epidemic Preparedness Innovations ("CEPI"). Expenses relating to these programs were previously presented separately, but are now aggregated for the prior period comparative.* 

*<sup>2</sup> This includes $0.1 million and $0.2 million for the six months ended June 30, 2025 and 2024, respectively, of personnel-related indirect expenses relating to time spent progressing the VTP-500 MERS program, which is funded by CEPI.*

&nbsp;&nbsp;&nbsp;&nbsp;· **General and Administrative Expenses:** General and administrative expenses were $15.4 million for the second quarter of 2025, compared to $12.6 million for first
quarter of 2025. The increase of $2.8 million relates primarily to an increase in unrealized losses on
foreign exchange driven mainly by translation of United States dollar balances in pound sterling denominated entities.

&nbsp;&nbsp;&nbsp;&nbsp;· **Net Loss:** For the
second quarter of 2025, the Company generated a net loss attributable to its shareholders of $21.1 million, or $(0.52) per share on both
basic and fully diluted bases, compared to a net loss attributable to its shareholders of $19.7 million, or $(0.49) per share on both
basic and fully diluted bases for the first quarter of 2025.

**About Barinthus Bio**

Barinthus Biotherapeutics (NASDAQ: BRNS) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic candidates for treating autoimmune and inflammatory diseases. Our guiding principle at the heart of Barinthus Bio is to help patients and their families by developing truly transformational and highly disease-specific immunotherapies that are potentially curative. Barinthus Bio's pipeline for I&I indications is enabled by our proprietary and highly differentiated platform for promoting immune tolerance, SNAP-TI, that is designed to guide a patient's T cells to a specific location to reduce inflammation and restore the natural state of immune non-responsiveness to healthy tissue. Our lead candidate, VTP-1000, is designed to restore immune non-responsiveness to gluten in patients with celiac disease and is currently in a Phase 1 clinical trial. Barinthus Bio's differentiated technology platform and therapeutic approach, coupled with deep scientific expertise and focus on clinical development, uniquely positions the company to navigate towards delivering treatments that improve the lives of people with autoimmune and inflammatory diseases. For more information, visit www.barinthusbio.com.

**Forward Looking Statements**

This press release contains forward-looking statements regarding Barinthus Bio within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, which can generally be identified as such by use of the words "may," "will," "plan," "forward," "encouraging," "believe," "potential," "expect," and similar expressions, although not all forward-looking statements contain these identifying words. These forward-looking statements include, without limitation, express or implied statements regarding our future expectations, plans and prospects, including our product development activities and clinical trials, including timing for readouts of any preliminary, interim or final data for any of our programs, the timing for initiation of any clinical trials, our anticipated regulatory filings and approvals, our cash runway and cash burn, our ability to develop and advance our current and future product candidates and programs, and our ability to establish and maintain collaborations or strategic relationships. Any forward-looking statements in this press release are based on our management's current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks and uncertainties related to the success, cost and timing of our pipeline development activities and planned and ongoing clinical trials, including the risk that the timing for preliminary, interim or final data or initiation of our clinical trials may be delayed, the risk that interim or topline data may not reflect final data or results, our ability to execute on our strategy, regulatory developments, the risk that we may not achieve the anticipated benefits of our pipeline prioritization and corporate restructuring, our ability to fund our operations and access capital, our cash runway, including the risk that our estimate of our cash runway may be incorrect, global economic uncertainty, including disruptions in the banking industry, the conflicts in Ukraine, Iran, Israel and Gaza, tariffs imposed by the U.S. and other countries and other risks identified in our filings with the Securities and Exchange Commission (the "SEC"), including our most recent annual report on Form 10-K and subsequent filings we may make with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We expressly disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

**BARINTHUS BIOTHERAPEUTICS PLC**

**CONSOLIDATED BALANCE SHEETS**

**(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS)**

**(UNAUDITED)**

---

| | | |
|:---|:---|:---|
|  | **As of<br> June 30,<br> 2025** | **As of<br> December 31,<br> 2024** |
| **ASSETS** |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $86259 | $110662 |
| &nbsp;&nbsp;&nbsp;Restricted cash | 1525 | 1738 |
| &nbsp;&nbsp;&nbsp;Research and development incentives receivable | 4536 | 7139 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets | 7681 | 6203 |
| &nbsp;&nbsp;&nbsp;Assets held for sale | 413 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 100414 | 125742 |
| &nbsp;&nbsp;&nbsp;Property and equipment, net | 4514 | 7373 |
| &nbsp;&nbsp;&nbsp;Intangible assets, net | 20366 | 21947 |
| &nbsp;&nbsp;&nbsp;Right of use assets, net | 3323 | 4384 |
| &nbsp;&nbsp;&nbsp;Other assets | 944 | 881 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $129561 | $160327 |
| **LIABILITIES AND STOCKHOLDERS' EQUITY** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | 1800 | 2474 |
| &nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 7364 | 9525 |
| &nbsp;&nbsp;&nbsp;Deferred income | 1525 | 1738 |
| &nbsp;&nbsp;&nbsp;Operating lease liability - current | 2036 | 1920 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 12725 | 15657 |
| Non-current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Operating lease liability - non-current | 9952 | 10087 |
| &nbsp;&nbsp;&nbsp;Contingent consideration | 2544 | 2650 |
| &nbsp;&nbsp;&nbsp;Other non-current liabilities | 1468 | 1360 |
| &nbsp;&nbsp;&nbsp;Deferred tax liability, net | 391 | 438 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | $27080 | $30192 |
| Commitments and contingencies (Note 15) |  |  |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;Ordinary shares, £0.000025 nominal value; 40,348,665 shares authorized, issued and outstanding (December 31, 2024: authorized, issued and outstanding: 40,234,663) | 1 | 1 |
| &nbsp;&nbsp;&nbsp;Deferred A shares, £1 nominal value; 63,443 shares authorized, issued and outstanding (December 31, 2024: authorized, issued and outstanding: 63,443) | 86 | 86 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 393663 | 393474 |
| &nbsp;&nbsp;&nbsp;Accumulated deficit | (278436) | (237664) |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss – foreign currency translation adjustments | (12937) | (25868) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity attributable to Barinthus Biotherapeutics plc shareholders | 102377 | 130029 |
| &nbsp;&nbsp;&nbsp;Noncontrolling interest | 104 | 106 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | $102481 | $130135 |
| Total liabilities and stockholders' equity | $129561 | $160327 |

---

**BARINTHUS BIOTHERAPEUTICS PLC**

**CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS**

**(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS)**

**(UNAUDITED)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **Three months ended** | **Three months ended** | **Six months ended** | **Six months ended** |
|  | **June 30, 2025** | **June 30, 2024** | **June 30, 2025** | **June 30, 2024** |
| Operating expenses |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Research and development | 7953 | 11662 | $16243 | $22787 |
| &nbsp;&nbsp;&nbsp;General and administrative | 15384 | 7201 | 28023 | 13195 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 23337 | 18863 | 44266 | 35982 |
| Other operating income | 13 | 577 | 342 | 782 |
| Loss from operations | (23324) | (18286) | (43924) | (35200) |
| Other income/(expense): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Interest income | 523 | 635 | 1079 | 1410 |
| &nbsp;&nbsp;&nbsp;Interest expense | (12) | (12) | (25) | (24) |
| &nbsp;&nbsp;&nbsp;Research and development incentives | 1342 | 693 | 1644 | 1287 |
| &nbsp;&nbsp;&nbsp;Other income | 320 | 20 | 395 | 20 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other income, net | 2173 | 1336 | 3093 | 2693 |
| Loss before income tax | (21151) | (16950) | (40831) | (32507) |
| Tax benefit | 25 | 7 | 47 | 44 |
| Net loss | (21126) | (16943) | (40784) | (32463) |
| &nbsp;&nbsp;&nbsp;Net loss attributable to noncontrolling interest | 2 | 12 | 12 | 43 |
| Net loss attributable to Barinthus Biotherapeutics plc shareholders | (21124) | (16931) | (40772) | (32420) |
| Weighted-average ordinary shares outstanding, basic | 40343521 | 39041111 | 40304584 | 38907296 |
| Weighted-average ordinary shares outstanding, diluted | 40343521 | 39041111 | 40304584 | 38907296 |
| Net loss per share attributable to ordinary shareholders, basic | $(0.52) | $(0.43) | $(1.01) | $(0.83) |
| Net loss per share attributable to ordinary shareholders, diluted | $(0.52) | $(0.43) | $(1.01) | $(0.83) |
| Net loss | $(21126) | $(16943) | $(40784) | $(32463) |
| Other comprehensive gain/(loss) – foreign currency translation adjustments | 8295 | 164 | 12941 | (1413) |
| Comprehensive loss | (12831) | (16779) | (27843) | (33876) |
| Comprehensive loss/(gain) attributable to noncontrolling interest | (5) | 11 | 2 | 39 |
| Comprehensive loss attributable to Barinthus Biotherapeutics plc shareholders | $(12836) | $(16768) | $(27841) | $(33837) |

---

**IR contact:**

Kevin Gardner

Managing Director

LifeSci Advisors

+1 617-283-2856

<u>kgardner@lifesciadvisors.com</u>

**Media contacts:**

Alexis Feinberg

Vice President

ICR Healthcare

<u>Alexis.feinberg@icrhealthcare.com</u>

Jonathan Edwards

Associate Partner

ICR Healthcare

<u>Barinthus@icrinc.com</u>

**Company contact:**

<u>ir@barinthusbio.com</u>